Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

Shares of Ocugen Inc. OCGN rallied 4.94% to $0.58 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 5,662.89 and Dow ...

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of dosing in the second cohort of the Phase 1 clinical trial for OCU200, a novel fusion protein ...

MALVERN, Pa. - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for eye diseases, has received approval from the Data and Safety Monitoring Board (DSMB) to proceed ...

MALVERN, Pa. - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for eye diseases, has received approval from the Data and Safety Monitoring Board (DSMB ...

Ocugen (OCGN) stock was up today after the biotech company posted results from its Q4 2024 earnings report. Earnings per share reported during ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market competition.